Australia markets closed

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.09+0.20 (+1.55%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.89
Open12.82
Bid6.59 x 1200
Ask19.33 x 1100
Day's range12.82 - 13.10
52-week range9.93 - 34.30
Volume1,820
Avg. volume3,166
Market cap565.695M
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)-3.26
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est31.13
  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at June 30, 2022

    Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a

  • GlobeNewswire

    Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

    Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, June 15, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manager

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022

    Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Credit Suis